122 related articles for article (PubMed ID: 19356086)
1. Oxidative bioactivation and toxicity of leflunomide in immortalized human hepatocytes and kinetics of the non-enzymatic conversion to its major metabolite, A77 1726.
Seah QM; New LS; Chan EC; Boelsterli UA
Drug Metab Lett; 2008 Aug; 2(3):153-7. PubMed ID: 19356086
[TBL] [Abstract][Full Text] [Related]
2. Hepatic cytochrome P450s attenuate the cytotoxicity induced by leflunomide and its active metabolite A77 1726 in primary cultured rat hepatocytes.
Shi Q; Yang X; Greenhaw J; Salminen WF
Toxicol Sci; 2011 Aug; 122(2):579-86. PubMed ID: 21546349
[TBL] [Abstract][Full Text] [Related]
3. Leflunomide or A77 1726 protect from acetaminophen-induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes.
Latchoumycandane C; Seah QM; Tan RC; Sattabongkot J; Beerheide W; Boelsterli UA
Toxicol Appl Pharmacol; 2006 Nov; 217(1):125-33. PubMed ID: 16979204
[TBL] [Abstract][Full Text] [Related]
4. The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis.
Vrenken TE; Buist-Homan M; Kalsbeek AJ; Faber KN; Moshage H
J Hepatol; 2008 Nov; 49(5):799-809. PubMed ID: 18809221
[TBL] [Abstract][Full Text] [Related]
5. The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes.
Palmer G; Burger D; Mezin F; Magne D; Gabay C; Dayer JM; Guerne PA
Arthritis Res Ther; 2004; 6(3):R181-9. PubMed ID: 15142263
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.
Ma LL; Wu ZT; Wang L; Zhang XF; Wang J; Chen C; Ni X; Lin YF; Cao YY; Luan Y; Pan GY
Acta Pharmacol Sin; 2016 Mar; 37(3):415-24. PubMed ID: 26806301
[TBL] [Abstract][Full Text] [Related]
7. In vitro metabolism of leflunomide by mouse and human liver microsomes.
Chan EC; New LS
Drug Metab Lett; 2007 Dec; 1(4):299-305. PubMed ID: 19356059
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Bohanec Grabar P; Grabnar I; Rozman B; Logar D; Tomsic M; Suput D; Trdan T; Peterlin Masic L; Mrhar A; Dolzan V
Drug Metab Dispos; 2009 Oct; 37(10):2061-8. PubMed ID: 19581389
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats.
Mehl ML; Tell L; Kyles AE; Chen YJ; Craigmill A; Gregory CR
J Vet Pharmacol Ther; 2012 Apr; 35(2):139-46. PubMed ID: 21615755
[TBL] [Abstract][Full Text] [Related]
10. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Moon SJ; Kim EK; Jhun JY; Lee HJ; Lee WS; Park SH; Cho ML; Min JK
J Transl Med; 2017 Feb; 15(1):31. PubMed ID: 28193225
[TBL] [Abstract][Full Text] [Related]
11. In vitro effects of the active metabolite of leflunomide, A77 1726, on feline herpesvirus-1.
Williams CR; Sykes JE; Mehl M; MacLeod JS; Lindsay LL; Poland AM; Chen YJ; Kyles AE; Waldman WJ; Gregory CR
Am J Vet Res; 2007 Sep; 68(9):1010-5. PubMed ID: 17764417
[TBL] [Abstract][Full Text] [Related]
12. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.
Xu X; Blinder L; Shen J; Gong H; Finnegan A; Williams JW; Chong AS
J Immunol; 1997 Jul; 159(1):167-74. PubMed ID: 9200452
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography.
Schmidt A; Schwind B; Gillich M; Brune K; Hinz B
Biomed Chromatogr; 2003 Jun; 17(4):276-81. PubMed ID: 12833393
[TBL] [Abstract][Full Text] [Related]
14. Leflunomide and malononitrilamides.
Silva Júnior HT; Morris RE
Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
[TBL] [Abstract][Full Text] [Related]
15. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
17. Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography.
Dias VC; Lucien J; LeGatt DF; Yatscoff RW
Ther Drug Monit; 1995 Feb; 17(1):84-8. PubMed ID: 7725383
[TBL] [Abstract][Full Text] [Related]
18. Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.
McLean JE; Neidhardt EA; Grossman TH; Hedstrom L
Biochemistry; 2001 Feb; 40(7):2194-200. PubMed ID: 11329288
[TBL] [Abstract][Full Text] [Related]
19. A rapid and simple determination of A77 1726 in human serum by high-performance liquid chromatography and its application for optimization of leflunomide therapy.
van Roon EN; Yska JP; Raemaekers J; Jansen TL; van Wanrooy M; Brouwers JR
J Pharm Biomed Anal; 2004 Sep; 36(1):17-22. PubMed ID: 15351043
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis.
Chan V; Charles BG; Tett SE
Br J Clin Pharmacol; 2005 Sep; 60(3):257-64. PubMed ID: 16120064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
